Mean self-reported body-weight loss by observation window among 60 adults who initiated compounded tirzepatide at 1–2 mg per week (PlexusDx retrospective analysis; medRxiv preprint posted Sept. 17, 2026; data frozen Sept. 2, 2026; not peer reviewed). Points show means; bars show 95% confidence intervals. The 36–59 and 60–89 day windows include only 19 and eight patients, respectively. No comparison group; weights were self-reported. Compounded tirzepatide is not an FDA-approved product.
Mean self-reported body-weight loss by observation window among 60 adults who initiated compounded tirzepatide at 1–2 mg per week (PlexusDx retrospective analysis; medRxiv preprint posted Sept. 17, 2026; data frozen Sept. 2, 2026; not peer reviewed). Points show means; bars show 95% confidence intervals. The 36–59 and 60–89 day windows include only 19 and eight patients, respectively. No comparison group; weights were self-reported. Compounded tirzepatide is not an FDA-approved product.